Trimebutine 3-thiocarbamoylbenzenesulfonate clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2012
How each study uses trimebutine 3-thiocarbamoylbenzenesulfonate is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
3 studies that test it; most in 2012 (1)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
gicare Pharma Inc. (3)
Studies
Open first, then newest update. How each study uses trimebutine 3-thiocarbamoylbenzenesulfonate is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full ColonoscopyCompletedPhase 2gicare Pharma Inc.NCT01926444Written as GIC-1001
- Study on Analgesia of GIC-1001 & GIC-1002 on Visceral Pain, Rectal Sensory Threshold Using the Barostat MethodCompletedPhase 1gicare Pharma Inc.NCT02276768Written as GIC-1001 375 mg TID
- A Clinical Phase I Study on GIC-1001 in Healthy VolunteersCompletedPhase 1gicare Pharma Inc.NCT01738425Written as GIC-1001; 125 mg oral tablets
Codes
What other systems call trimebutine 3-thiocarbamoylbenzenesulfonate · ClinicalTrials.gg INT000405
- MeSH (NLM) C000605012trimebutine 3-thiocarbamoylbenzenesulfonateOne source NLM
- UNII (FDA) 5O1CF9IS48TRIMEBUTINE 3-THIOCARBAMOYLBENZENESULFONATEConfirmed FDA, NLM
- NCI Thesaurus C111045Trimebutine 3-ThiocarbamoylbenzenesulfonateOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000605012 | trimebutine 3-thiocarbamoylbenzenesulfonate | One source NLM |
| UNII (FDA) | 5O1CF9IS48 | TRIMEBUTINE 3-THIOCARBAMOYLBENZENESULFONATE | Confirmed FDA, NLM |
| NCI Thesaurus | C111045 | Trimebutine 3-Thiocarbamoylbenzenesulfonate | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.